Admissions to hospital and sick leave in patients with AS before and 1 or 2 years after treatment with infliximab
| Two year completers (n = 49) | p Value (completers) | Withdrawals/dropouts (n = 20) | Total (n = 69) | p Value (total) | |
|---|---|---|---|---|---|
| NA, not applicable, because of incomplete data for the dropouts in the second year. | |||||
| p value: comparison with the period before treatment by the McNemar or Wilcoxon tests, as appropriate. | |||||
| Admissions to hospital past 12 months | |||||
| Patients, No (%) | |||||
| Before treatment | 20 (41) | 6 (30) | 26 (38) | ||
| After 1 year of treatment | 5 (10) | 0.001 | 6 (30) | 11 (16) | 0.008 |
| After 2 years of treatment | 5 (10) | 0.001 | NA | NA | |
| Inpatient days for each patient treated, mean (range) | |||||
| Before treatment | 11.1 (0–77) | 7.7 (0–63) | 10.1 (0–77) | ||
| After 1 year of treatment | 0.6 (0–15) | <0.001 | 5.6 (0–54) | 2.0 (0–54) | 0.001 |
| After 2 years of treatment | 2.9 (0–72) | 0.007 | NA | NA | |
| Employed patients at the time of the study | (n = 28) | (n = 10) | (n = 38) | ||
| On sick leave during the past 12 months, No (%) | |||||
| Before treatment | 16 (57) | 5 (50) | 21 (55) | ||
| After 1 year of treatment | 10 (36) | 0.031 | 7 (70) | 17 (45) | 0.29 |
| After 2 years of treatment | 4 (14) | <0.001 | NA | NA | |
| Days on sick leave for each employed patient, mean (range) | |||||
| Before treatment | 31.3 (0–365) | 67.6 (0–365) | 40.9 (0–365) | ||
| After 1 year of treatment | 12.5 (0–84) | 0.009 | 66.5 (0–273) | 26.7 (0–273) | 0.046 |
| After 2 years of treatment | 4.7 (0–55) | 0.002 | NA | NA | |